• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

HeavenlyRx To Acquire Industry-Leading CBD Brand PureKana

Share:

October 7, 2019

  • PureKana will join HeavenlyRx’s highly differentiated and rapidly expanding family of brands
  • PureKana has accelerated its revenue growth since its founding in 2017, and is projected to more than double its revenue by 2020

HeavenlyRx Ltd. (“HeavenlyRx”), a global hemp and CBD company, is pleased to enter into a signed letter of intent (“LOI”) to acquire the top-ranked national CBD brand, PureKana (“PureKana” or the “Company”). Under the agreement, HeavenlyRx will acquire a majority ownership stake from the Company’s founding members with the acquisition expected to close by the end of 2019.

Standing alongside HeavenlyRx’s high ethos and quality standards, PureKana – located in Scottsdale, Arizona – is a rapidly growing CBD brand and company with a large consumer base that leans toward a young and active demographic. Their robust line of ultra-concentrated hemp CBD products are non-GMO and fully derived from organically grown hemp without the use of genetically modified organisms and can be used in foods and nutritional additives. Once harvested, their hemp is carefully processed and undergoes extraction and quality testing, creating a rich, ultra-concentrated CBD oil which is infused in their product lineup that spans oils, capsules, topicals, gummies and pet products. Legal in all 50 U.S. states, PureKana’s products meet the highest standard of excellence and all safety requirements as put forth by the Food and Drug Administration (FDA).

PureKana, led by Founder and CEO Cody Alt, has consistently accelerated its revenue growth year after year, and expects to continue this trend. Currently, the majority of PureKana’s sales come from online and ecommerce. In the coming year, however, the brand with HeavenlyRx’s strategic selling capabilities plans to expand into major retailers and other retail environments.

“PureKana has grown into one of the most important brands in the CBD industry,” said HeavenlyRx CEO Paul Norman. “With a dynamic entrepreneur and business leader like Cody Alt leading the helm, his vision to bring PureKana into the mainstream is a great fit for HeavenlyRx. PureKana’s powerful online presence when combined with our reach to distribution into mainstream channels will create a leading player in the marketplace.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Date: October 07, 2019

Source: PR Newswire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Covid-19 Impact on Global e-Pharma Market Segmentation, Analysis by Recent Trends, Development & Growth by RegionsCovid-19 Impact on Global e-Pharma Market Segmentation, Analysis by Recent Trends, Development & Growth by Regions
  • Adapthealth Signs Definitive Agreement to Acquire Patient Care Solutions Business from Mckesson CorporationAdapthealth Signs Definitive Agreement to Acquire Patient Care Solutions Business from Mckesson Corporation
  • InterSystems Announces Clean Data as a SolutionInterSystems Announces Clean Data as a Solution
  • AI is best leveraged when it’s tied to outcomesAI is best leveraged when it’s tied to outcomes
  • Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera TherapeuticsLexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics
  • Cellex Becomes First Company to Land FDA Emergency Use Authorization for COVID-19 Serology TestingCellex Becomes First Company to Land FDA Emergency Use Authorization for COVID-19 Serology Testing
  • EVERSANA™ Announces an Agreement to Acquire Cornerstone Research Group; Adds Global HEOR Capabilities to Integrated Commercial Services PlatformEVERSANA™ Announces an Agreement to Acquire Cornerstone Research Group; Adds Global HEOR Capabilities to Integrated Commercial Services Platform
  • Bicycle Health, Albertsons Partner to Boost Access to Opioid use Disorder InjectionsBicycle Health, Albertsons Partner to Boost Access to Opioid use Disorder Injections

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications